Retinoblastoma
information center
This website includes information on the eye
cancer, Retinoblastoma. This cancer is often
found in young children and can possibly be
life threatening.
Book a Consult
Retinoblastoma is a eye cancer found in young
What is
Retinoblastoma?
children usually under the age of 5 with most cases
diagnosed before age 2.
Rare aggressive cancer
tumour of the retina usually
seen in young kids (2 and
under USUALLY)
Can cause blindness,
destroy the eye and can
possibly be fatal if not
treated
Can spread to the brain or
spine
Can result in eye removal
Statistics
Global Incidence: Estimated at 1 in 14,000 to 1 in 20,000 live births.
Annual Cases: Approximately 8,000 to 9,000 new cases are diagnosed worldwide each year, with around 300–350 in the
United States.
Age at Diagnosis: Median age is 12 months for bilateral (both eyes) cases and 24 months for unilateral (one eye) cases.
Progression: 90% of cases are diagnosed before age 3.
Laterality and Heredity
Unilateral (One Eye): Accounts for 55–60% of cases, with a median diagnosis age of 24
months.
Bilateral (Both Eyes): Accounts for 25–40% of cases, with a median diagnosis age of 12
months.
Hereditary/Germline: Approximately 40–45% of cases are inherited, often resulting in
bilateral disease.
Sporadic/Nonhereditary: Roughly 55–60% of cases are sporadic, usually involving only one
eye.
Who does it affect?
1 in 15,000-16,000 births
1 in 15,000-16,000 births will be
born with the condition.
Youth
Genetics
Young children, usually under
While often sporadic, the hereditary
the age of 5 and most cases are
form is passed from parent to child
diagnosed before age 2
or occurs as a new mutation in the
germline.
How can
we fix it?
Ways to cure
Intra-arterial Chemotherapy (OAC):
Intravitreal Chemotherapy:
Focal Therapies:
Cryotherapy: Freezing the tumor cells.
survival rates exceeding 95-99% in
developed countries when caught early.
There is no single "cure" in the sense of a
pill, but it is "fixed" through a combination of
targeted therapies aimed at saving the child's
life, then the eye, and finally, preserving
vision
Treatment is managed by a team of pediatric
oncology specialists and depends on whether
the tumor is in one eye (unilateral) or both
(bilateral).
Laser Therapy (Thermotherapy):
Plaque Radiotherapy (Brachytherapy):
Enucleation (Surgery):Systemic Chemotherapy:
“No cure”
While the survival rate is high, "no
cure" usually refers to situations where
the cancer has spread beyond the eye
or, in hereditary cases, causes new,
separate cancers.
Statistics
Global Incidence: Estimated at 1 in 14,000 to 1 in 20,000 live births.
Annual Cases: Approximately 8,000 to 9,000 new cases are diagnosed worldwide each year, with around 300–350 in the
United States.
Age at Diagnosis: Median age is 12 months for bilateral (both eyes) cases and 24 months for unilateral (one eye) cases.
Progression: 90% of cases are diagnosed before age 3.
Laterality and Heredity
Unilateral (One Eye): Accounts for 55–60% of cases, with a median diagnosis age of 24
months.
Bilateral (Both Eyes): Accounts for 25–40% of cases, with a median diagnosis age of 12
months.
Hereditary/Germline: Approximately 40–45% of cases are inherited, often resulting in
bilateral disease.
Sporadic/Nonhereditary: Roughly 55–60% of cases are sporadic, usually involving only one
eye.
Survival and Outcomes
High-Income Countries (HICs): 5-year
survival rates exceed 95–98%.
Survival
While retinoblastoma is a very serious
Low- and Middle-Income Countries (LMICs):
3-year survival rates are significantly lower,
sometimes as low as 30–60%.
disease, if treated early on it has a almost
Mortality: In LMICs, delayed diagnosis leads
certain chance of survival
to high mortality, with up to 25% of children in
some African regions dying within 1 year.
Risk of Second Cancer: Survivors of
hereditary retinoblastoma have a 6% risk of
developing a secondary malignancy,
increasing fivefold with external beam
radiation therapy (EBRT).
Genetic Factors
RB1 Gene: Mutations in the
Inheritance: Follows an autosomal
Sibling Risk: If both parents are
RB1 tumor suppressor gene are
dominant pattern with high
unaffected, siblings of a child
the primary cause, following
penetrance.
with retinoblastoma have a 4%
Knudson's "two-hit" hypothesis.
to 7% risk of developing the
condition.
https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/retinoblastoma
Most children with retinoblastoma in the developed
world are cured today. However, even after cure,
Effects of
Retinoblastoma
the ghost of cancer walks with many survivors
throughout life. Emotions, impaired vision and
other effects of treatment, life-long second cancer
risk and adapting to meet the challenges of the
world can be hard. But life after retinoblastoma can
also be richly blessed and full of living, with
knowledge, understanding and the right support.
Retinoblastoma can affect
education in young children
because without a fully
functioning set of eyes, it is
much harder to learn in normal
schools
Pro’s and con’s of treatments
Pros:
High Survival Rates: In developed countries, the survival rate
for retinoblastoma exceeds 95%, making it a highly curable
cancer when diagnosed and treated early. Untreated, the
cancer can spread (metastasize) and become life-threatening.
Vision Preservation: Modern, targeted therapies (such as
intra-arterial and intravitreal chemotherapy, laser therapy,
and cryotherapy) are designed to control the cancer while
preserving as much vision as possible.
Eye Preservation: Advanced techniques have drastically
increased the rate of eye salvage, preventing the need for
enucleation (surgical removal of the eye) in many cases.
Improved Quality of Life: Preserving vision and the eye
helps avoid the physical and psychological impacts
associated with eye loss, such as potential changes in facial
bone growth in young children and self-esteem issues.
Prevention of Metastasis: Effective local and systemic
treatment stops the cancer from spreading to other parts of
the body, which is crucial for long-term survival.
Side effects / cons
Secondary Cancers: Survivors, especially those with the heritable form of the
disease or those treated with external beam radiation (EBRT) combined with
chemotherapy, have a higher risk of developing a second cancer (e.g.,
osteosarcoma, melanoma, brain tumors) later in life. The risk is generally
considered to be outweighed by the immediate benefit of treating the
retinoblastoma.
Vision Impairment: The cancer itself or treatments like radiation, laser therapy, or
intense chemotherapy can damage healthy retinal cells and blood vessels,
potentially leading to a range of vision problems, including cataracts, dry eyes,
floaters, or even partial or total vision loss in the affected eye.
Physical Changes:
Enucleation (eye removal): May lead to the need for an artificial eye (ocular
prosthesis) and, if not properly managed with a conformer or implant, potential
changes in the shape and size of the surrounding facial bones in a growing
child.
Radiation: Can cause damage to the bone around the eye (orbital hypoplasia),
potentially leading to minor facial asymmetry.
Systemic Side Effects of Chemotherapy: Depending on the drugs used, potential
side effects can include hearing loss (ototoxicity, especially from carboplatin),
reduced immune function and risk of infection (due to low white blood cell
counts), and in rare cases, other long-term organ issues (kidney, heart problems).
Psychosocial Impact: Children and their families may need time and support to
adjust to the physical and emotional changes resulting from the diagnosis and
treatment.
Refrences
Fabian, I. D., Abdallah, E., Abdullahi, S. U., Abdulqader, R. A., Boubacar, S. A., Ademola-Popoola, D. S., … Global
Retinoblastoma Study Group. (2020). Global retinoblastoma presentation and analysis by national income level.
https://www.sciencedirect.com/science/article/pii/S2468124520300279
National Center for Biotechnology Information. (2023). Retinoblastoma. In StatPearls.
https://www.ncbi.nlm.nih.gov/books/NBK545276/
Temming, P., Arendt, M., Viehmann, A., Eisele, L., Le Guin, C. H. D., Schündeln, M. M., Biewald, E., Mäusert, J.,
Wieland, R., Bornfeld, N., Sauerwein, W., Eggert, A., Lohmann, D. R., & Jöckel, K.-H. (2016). How eye-preserving
therapy affects long-term overall survival in heritable retinoblastoma survivors. Journal of Clinical Oncology,
34(26), 3183–3188. https://doi.org/10.1200/JCO.2015.65.4012